1. Lumasiran was shown to decrease urinary oxalate excretion in patients with Primary Hyperoxaluria Type 1.
2. Lumasiran was shown not to cause severe or serious adverse events.
Evidence Rating Level: 1 (Excellent)
Study Rundown: Oxalate is the toxic metabolite overproduced by the liver in Primary Hyperoxaluria Type 1 (PH1). The elevated...